참고문헌
- Ahmad S, Gromiha M, Fawareh H, Sarai A (2004). ASAView: database and tool for solvent accessibility representation in proteins. BMC bioinformatics, 5, 51. https://doi.org/10.1186/1471-2105-5-51
- Bandaru S, Marri VK, Kasera P, et al (2014). Structure based virtual screening of ligands to identify cysteinyl leukotriene receptor 1 antagonist. Bioinformat, 10, 652. https://doi.org/10.6026/97320630010652
- Basse MJ, Betzi S, Bourgeas R, et al (2013). 2P2Idb: a structural database dedicated to orthosteric modulation of protein-protein interactions. Nucleic Acids Res, 41, 824-27. https://doi.org/10.1093/nar/gks1002
- Chen J, Marechal V, Levine AJ (1993). Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol, 13, 4107-14. https://doi.org/10.1128/MCB.13.7.4107
- Cheng F, Li W, Zhou Y, et al (2012). admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model, 52, 3099-105. https://doi.org/10.1021/ci300367a
- DeLeo AB, Jay G, Appella E, Dubois GC, et al (1979). Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A, 76, 2420-4. https://doi.org/10.1073/pnas.76.5.2420
- Feki A, Irminger-Finger I (2004). Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol, 52, 103-16. https://doi.org/10.1016/j.critrevonc.2004.07.002
- Freedman DA, Levine AJ (1998). Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol, 18, 7288-93. https://doi.org/10.1128/MCB.18.12.7288
- Fridman JS, Lowe SW (2003). Control of apoptosis by p53. Oncogene, 22, 9030-40. https://doi.org/10.1038/sj.onc.1207116
- Haupt Y, Maya R, Kazaz A, Oren M (1997). MDM2 promotes the rapid degradation of p53. Nature, 387, 296-9. https://doi.org/10.1038/387296a0
- Lane DP, Crawford LV (1979). T antigen is bound to a host protein in SV40-transformed cells. Nature, 278, 261-3. https://doi.org/10.1038/278261a0
- Linzer DI, Levine AJ (1979). Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell, 17, 43-52. https://doi.org/10.1016/0092-8674(79)90293-9
- Liu J, Zheng Y, Lei D, et al (2011). MDM2 309T> G polymorphism and risk of squamous cell carcinomas of head and neck: a meta-analysis. Asian Pac J Cancer Prev, 12, 1899-03.
- Maunz A, Gutlein M, Rautenberg M, et al (2013). Lazar: a modular predictive toxicology framework. Front Pharmacol, 4, 38.
- Momand J, Jung D, Wilczynski S, Niland J (1998). The MDM2 gene amplification database. Nucleic Acids Res, 26, 3453-9. https://doi.org/10.1093/nar/26.15.3453
- Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53- mediated transactivation. Cell, 69, 1237-45. https://doi.org/10.1016/0092-8674(92)90644-R
- Nelder JA, Mead R (1965). A simplex method for function minimization. Comput J, 7, 308-13. https://doi.org/10.1093/comjnl/7.4.308
- Oliner JD, Kinzler KW, Meltzer PS, et al (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358, 80-3. https://doi.org/10.1038/358080a0
- Patton JT, Mayo LD, Singhi AD, et al (2006). Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin- 3. Cancer Res, 66, 3169-76. https://doi.org/10.1158/0008-5472.CAN-05-3832
- Ray-Coquard I, Blay JY, Italiano A, et al (2012). Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol, 13, 1133-40. https://doi.org/10.1016/S1470-2045(12)70474-6
- Reichmann D, Phillip Y, Carmi A, Schreiber G (2008). On the contribution of water-mediated interactions to protein-complex stability. Biochem, 47, 1051-60. https://doi.org/10.1021/bi7019639
- Sarek G, Kurki S, Enback J, et al (2007). Reactivation of the p53 pathway as a treatment modality for KSHVinduced lymphomas. J Clin Invest, 117, 1019-28. https://doi.org/10.1172/JCI30945
- Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ (2005). PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res, 33, 363-67. https://doi.org/10.1093/nar/gki481
- Shangary S, Qin D, McEachern D, et al (2008). Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA, 105, 3933-8. https://doi.org/10.1073/pnas.0708917105
- Srivatanakul P, Sriplung H (2004). Epidemiology of liver cancer: an overview. Asian Pac J Cancer Prev, 5, 118-25
- Stakleff KS, Sloan T, Blanco D, et al (2012). Resveratrol exerts differential effects in vitro and in vivo against ovarian cancer cells. Asian Pac J Cancer Prev, 13, 1333-40. https://doi.org/10.7314/APJCP.2012.13.4.1333
- Teodoro JG, Evans SK, GreenMR (2007). Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med, 85, 1175-86. https://doi.org/10.1007/s00109-007-0221-2
- Thomsen R, Christensen MH (2006). MolDock: a new technique for high-accuracy molecular docking. J Med Chem, 49, 3315-21. https://doi.org/10.1021/jm051197e
- Chanda Sinha, Anuradha Nischal, Srinivas Bandaru, et al (2015). An In silico Approach for Identification of Novel Inhibitors as a Potential Therapeutics Targeting HIV-1 Viral Infectivity Factor. Current Topics Med Chem, 15, 65-72. https://doi.org/10.2174/1568026615666150112114337
- Tian, X, Tian Y, Ma P, et al (2013). Association between MDM2 SNP309 T>G and risk of gastric cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 1925-9. https://doi.org/10.7314/APJCP.2013.14.3.1925
- Tovar C, Rosinski J, Filipovic Z, et al (2006). Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A, 103, 1888-93. https://doi.org/10.1073/pnas.0507493103
- Vassilev LT, Vu BT, Graves B, et al (2004). In vivo activation of the p53 pathway by small molecule antagonists of MDM2. Science, 303, 844-8. https://doi.org/10.1126/science.1092472
- Vassilev LT,Vu BT,Graves B, et al (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 303, 844-8. https://doi.org/10.1126/science.1092472
- Vousden KH, Lu X (2002). Live or let die: the cell's response to p53. Nat Rev Cancer, 2, 594-604. https://doi.org/10.1038/nrc864
- Wu X, Bayle JH, Olson D, Levine AJ (1993). The p53-mdm-2 autoregulatory feedback loop. Genes Dev, 7, 1126-32. https://doi.org/10.1101/gad.7.7a.1126
- Xu T, Xu ZC, Zou Q, Yu B et al (2012). P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54. https://doi.org/10.7314/APJCP.2012.13.5.2349
- Yang JM, Chen CC (2004). Gemdock: A generic evolutionary method for molecular docking. Proteins, 55, 288-304. https://doi.org/10.1002/prot.20035
- Yang ZH, Zhou CL, Zhu H et al (2014). A functional SNP in the MDM2 promoter mediates E2F1 affinity to modulate cyclin D1 expression in tumor cell proliferation. Asian Pac J Cancer Prev, 15, 3817. https://doi.org/10.7314/APJCP.2014.15.8.3817